Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence

OBJECTIVE: Adalimumab has proven effective in psoriasis; however, secondary failure may result from the drug's immunogenicity. Prevalence data on the immunogenicity of biologicals, and of adalimumab in particular, are highly variable. We investigated the prevalence of anti-adalimumab antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, G, Perego, S, Sansoni, V, Diani, M, Banfi, G, Altomare, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168630/
https://www.ncbi.nlm.nih.gov/pubmed/27940624
http://dx.doi.org/10.1136/bmjopen-2016-011941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168630/
https://www.ncbi.nlm.nih.gov/pubmed/27940624
http://dx.doi.org/10.1136/bmjopen-2016-011941

Ejemplares similares